CA3073998A1 - Improved treatment of atopic dermatitis with tradipitant - Google Patents
Improved treatment of atopic dermatitis with tradipitant Download PDFInfo
- Publication number
- CA3073998A1 CA3073998A1 CA3073998A CA3073998A CA3073998A1 CA 3073998 A1 CA3073998 A1 CA 3073998A1 CA 3073998 A CA3073998 A CA 3073998A CA 3073998 A CA3073998 A CA 3073998A CA 3073998 A1 CA3073998 A1 CA 3073998A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- tradipitant
- treatment
- genotype
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US62/558,303 | 2017-09-13 | ||
| US201762572456P | 2017-10-14 | 2017-10-14 | |
| US62/572,456 | 2017-10-14 | ||
| PCT/US2018/048825 WO2019055225A1 (en) | 2017-09-13 | 2018-08-30 | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3073998A1 true CA3073998A1 (en) | 2019-03-21 |
Family
ID=63684468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073998A Pending CA3073998A1 (en) | 2017-09-13 | 2018-08-30 | Improved treatment of atopic dermatitis with tradipitant |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (https=) |
| EP (2) | EP4487912A3 (https=) |
| JP (1) | JP7347743B2 (https=) |
| KR (2) | KR20200054232A (https=) |
| CN (1) | CN111093671A (https=) |
| AU (1) | AU2018331267B2 (https=) |
| CA (1) | CA3073998A1 (https=) |
| CL (1) | CL2020000655A1 (https=) |
| IL (1) | IL272949B2 (https=) |
| MX (2) | MX2020002852A (https=) |
| WO (1) | WO2019055225A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| CN112218636B (zh) | 2018-06-08 | 2025-05-06 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
| JP2023515167A (ja) * | 2020-02-25 | 2023-04-12 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによるアトピー性皮膚炎の改善された治療 |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| PL3996169T3 (pl) | 2020-05-07 | 2025-05-12 | Lg Energy Solution, Ltd. | Wysokoniklowy arkusz elektrody i sposób jego wytwarzania |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| CN120641099A (zh) | 2022-12-21 | 2025-09-12 | 万达制药公司 | 使用曲地匹坦的治疗方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (https=) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| KR100755577B1 (ko) | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
| BR0309486A (pt) | 2002-04-26 | 2005-02-09 | Lilly Co Eli | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| NZ580480A (en) | 2003-10-24 | 2010-02-26 | Lilly Co Eli | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| WO2007096782A2 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
| CN101568523A (zh) | 2006-12-20 | 2009-10-28 | 伊莱利利公司 | 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法 |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| BR112015031724A2 (pt) | 2013-06-24 | 2017-07-25 | Tigercat Pharma Inc | uso do antagonista do receptor nk-1 serlopitant em pruridos |
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
-
2018
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en not_active Ceased
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
- 2018-08-30 IL IL272949A patent/IL272949B2/en unknown
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Ceased
- 2018-08-30 EP EP24211922.0A patent/EP4487912A3/en active Pending
- 2018-08-30 KR KR1020257006413A patent/KR20250036264A/ko active Pending
- 2018-08-30 EP EP18778635.5A patent/EP3681505B1/en active Active
-
2020
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
- 2020-03-13 MX MX2024004377A patent/MX2024004377A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018331267A1 (en) | 2020-04-16 |
| EP4487912A3 (en) | 2025-03-26 |
| MX2024004377A (es) | 2024-04-26 |
| WO2019055225A1 (en) | 2019-03-21 |
| MX2020002852A (es) | 2020-07-22 |
| CN111093671A (zh) | 2020-05-01 |
| EP3681505C0 (en) | 2024-12-18 |
| AU2018331267B2 (en) | 2024-03-07 |
| EP3681505B1 (en) | 2024-12-18 |
| CL2020000655A1 (es) | 2020-10-09 |
| IL272949B2 (en) | 2025-07-01 |
| IL272949B1 (en) | 2025-03-01 |
| IL272949A (en) | 2020-04-30 |
| JP7347743B2 (ja) | 2023-09-20 |
| JP2020533381A (ja) | 2020-11-19 |
| EP4487912A2 (en) | 2025-01-08 |
| US20210062262A1 (en) | 2021-03-04 |
| RU2020112222A (ru) | 2021-10-13 |
| US11549147B2 (en) | 2023-01-10 |
| KR20200054232A (ko) | 2020-05-19 |
| BR112020004964A2 (pt) | 2020-09-15 |
| EP3681505A1 (en) | 2020-07-22 |
| KR20250036264A (ko) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018331267B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Yoshida et al. | Skin barrier defects in atopic dermatitis: from old idea to new opportunity | |
| Hawkins et al. | The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthma | |
| Horak et al. | The CRTH 2 antagonist OC 000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo‐controlled, double‐blind trial | |
| Minoguchi et al. | Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast | |
| Rabinovitch et al. | Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma | |
| EP4005570B1 (en) | Pridopidine for use in treating rett syndrome | |
| Muñoz et al. | Glycomacropeptide attenuates inflammation, pruritus, and Th2 response associated with atopic dermatitis induced by 2, 4‐dinitrochlorobenzene in rat | |
| Chen et al. | Potassium channels related to primary aldosteronism: Expression similarities and differences between human and rat adrenals | |
| Higashihara et al. | Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD | |
| Yen et al. | Identification of phenothiazine as an ETV1-targeting agent in gastrointestinal stromal tumors using the Connectivity Map | |
| Miyata et al. | UDP-glucuronosyltransferase 1A1* 6 and* 28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer | |
| Carter et al. | Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344× Brown Norway rats | |
| Ortega et al. | A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma | |
| EA024450B1 (ru) | Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости | |
| Terashima et al. | Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor | |
| JP2025134747A (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| Yuferov et al. | Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: effect on age trajectory of heroin use | |
| US20230073637A1 (en) | Treatment of atopic dermatitis with tradipitant | |
| JP2025000672A (ja) | Ｌｏｕ０６４を使用した治療の方法 | |
| RU2812890C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| RU2793237C2 (ru) | Усовершенствованное лечение атопического дерматита традипитантом | |
| Antoniu | Novel therapies for hypereosinophilic syndromes | |
| Zhang et al. | Protease-activated receptors expression in gingiva in periodontal health and disease | |
| BR112020004964B1 (pt) | Método para determinar uma dose eficaz de tradipitant ou um sal farmaceuticamente aceitável do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230816 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240823 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240823 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240823 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240906 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250617 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250822 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250822 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260218 |